CN111699174A - 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 - Google Patents
一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 Download PDFInfo
- Publication number
- CN111699174A CN111699174A CN201980012692.2A CN201980012692A CN111699174A CN 111699174 A CN111699174 A CN 111699174A CN 201980012692 A CN201980012692 A CN 201980012692A CN 111699174 A CN111699174 A CN 111699174A
- Authority
- CN
- China
- Prior art keywords
- fluoroquinolin
- spiro
- carboxamide
- nonane
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种吲哚胺‑2,3‑双加氧酶抑制剂及其制备方法。本发明的抑制剂,结构如通式(I)所示,其中,Ar、E、Y、X、V、D、W、B、环A和环B的定义如说明书和权利要求书中所示。本发明还公开了该抑制剂的制备方法。本发明的通式(I)化合物可以作为吲哚胺‑2,3‑双加氧酶抑制剂,用于制备预防和/或治疗吲哚胺‑2,3‑双加氧酶介导的疾病的药物。
Description
PCT国内申请,说明书已公开。
Claims (17)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810150080.7A CN110156674A (zh) | 2018-02-13 | 2018-02-13 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
CN2018101500807 | 2018-02-13 | ||
PCT/CN2019/074855 WO2019158051A1 (zh) | 2018-02-13 | 2019-02-12 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111699174A true CN111699174A (zh) | 2020-09-22 |
Family
ID=67619736
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810150080.7A Pending CN110156674A (zh) | 2018-02-13 | 2018-02-13 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
CN201980012692.2A Pending CN111699174A (zh) | 2018-02-13 | 2019-02-12 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810150080.7A Pending CN110156674A (zh) | 2018-02-13 | 2018-02-13 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210047290A1 (zh) |
EP (1) | EP3753926A4 (zh) |
JP (1) | JP7106659B2 (zh) |
CN (2) | CN110156674A (zh) |
WO (1) | WO2019158051A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019078968A2 (en) * | 2017-10-18 | 2019-04-25 | Angex Pharmaceutical, Inc. | CYCLIC COMPOUNDS AS IMMUNOMODULATORS |
CN111406050B (zh) * | 2018-01-17 | 2023-02-03 | 厦门宝太生物科技股份有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其用途 |
EP3858813A4 (en) * | 2018-09-27 | 2022-06-22 | Shenzhen Chipscreen Biosciences Co., Ltd. | QUINOLONE DERIVATIVE WITH INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101312976A (zh) * | 2005-11-23 | 2008-11-26 | 默克公司 | 作为hdac抑制剂的螺环化合物 |
CN105732636A (zh) * | 2014-12-30 | 2016-07-06 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
WO2017192840A1 (en) * | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2018008711A1 (ja) * | 2016-07-07 | 2018-01-11 | 小野薬品工業株式会社 | Ep4拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007514A1 (en) | 1992-09-29 | 1994-04-14 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
CN101212967A (zh) | 2005-05-10 | 2008-07-02 | 因塞特公司 | 吲哚胺2,3-双加氧酶调节剂及其用法 |
AU2006282955A1 (en) | 2005-08-26 | 2007-03-01 | Merck & Co., Inc. | Diazaspirodecane orexin receptor antagonists |
JP2010517966A (ja) | 2007-02-01 | 2010-05-27 | グラクソ グループ リミテッド | 摂食障害の処置のための1−オキサ−3−アザスピロ(4.5)デカン−2−オンおよび1−オキサ−3,8−ジアザスピロ(4.5)デカン−2−オン誘導体 |
JP2010155827A (ja) | 2008-12-04 | 2010-07-15 | Takeda Chem Ind Ltd | スピロ環化合物 |
WO2012047703A2 (en) | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
WO2013105998A2 (en) * | 2011-02-16 | 2013-07-18 | Tyco Electronics Corporation | Fiber optic closure |
AU2013209958B2 (en) | 2012-01-16 | 2017-09-07 | Vertex Pharmaceuticals Incorporated | Pyran-spirocyclic piperidine amides as modulators of ion channels |
US10162439B2 (en) * | 2012-02-14 | 2018-12-25 | Koninklijke Philips N.V. | Shock touch protection of a mobile device |
CN105481789B (zh) | 2014-09-15 | 2020-05-19 | 中国科学院上海有机化学研究所 | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 |
CA2965741C (en) | 2014-11-03 | 2022-05-17 | Iomet Pharma Ltd | Pharmaceutical compound |
US10161826B2 (en) * | 2016-05-04 | 2018-12-25 | International Business Machines Corporation | Method and apparatus for inducing multiaxial excitation |
JP2020534336A (ja) | 2017-09-20 | 2020-11-26 | ハンジョウ イノゲート ファーマ カンパニー リミテッドHangzhou Innogate Pharma Co., Ltd. | Ido阻害剤および/またはido−hdac二重阻害剤としての多環式化合物 |
WO2019078968A2 (en) * | 2017-10-18 | 2019-04-25 | Angex Pharmaceutical, Inc. | CYCLIC COMPOUNDS AS IMMUNOMODULATORS |
JP2021501164A (ja) | 2017-10-30 | 2021-01-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | インドールアミン2,3−ジオキシゲナーゼのモジュレーター |
-
2018
- 2018-02-13 CN CN201810150080.7A patent/CN110156674A/zh active Pending
-
2019
- 2019-02-12 EP EP19754006.5A patent/EP3753926A4/en active Pending
- 2019-02-12 WO PCT/CN2019/074855 patent/WO2019158051A1/zh unknown
- 2019-02-12 JP JP2020543331A patent/JP7106659B2/ja active Active
- 2019-02-12 US US16/969,307 patent/US20210047290A1/en active Pending
- 2019-02-12 CN CN201980012692.2A patent/CN111699174A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101312976A (zh) * | 2005-11-23 | 2008-11-26 | 默克公司 | 作为hdac抑制剂的螺环化合物 |
CN105732636A (zh) * | 2014-12-30 | 2016-07-06 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
WO2017192840A1 (en) * | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
WO2018008711A1 (ja) * | 2016-07-07 | 2018-01-11 | 小野薬品工業株式会社 | Ep4拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ |
Also Published As
Publication number | Publication date |
---|---|
US20210047290A1 (en) | 2021-02-18 |
CN110156674A (zh) | 2019-08-23 |
JP2021513549A (ja) | 2021-05-27 |
EP3753926A1 (en) | 2020-12-23 |
WO2019158051A1 (zh) | 2019-08-22 |
JP7106659B2 (ja) | 2022-07-26 |
EP3753926A4 (en) | 2021-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI674257B (zh) | 作為trpm8拮抗劑之氮雜螺衍生物 | |
CN105481789B (zh) | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 | |
CA3149926A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
CN107176933B (zh) | 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂 | |
CN111770756B (zh) | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 | |
TW201630891A (zh) | 三環性螺化合物 | |
CN112543755A (zh) | 一类细胞坏死抑制剂及其制备方法和用途 | |
CN111699174A (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的螺环化合物 | |
WO2011140078A1 (en) | Synthetic triterpenoid derivatives | |
WO2023280136A1 (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
US20230265072A1 (en) | Substituted pyrazolo piperidine carboxylic acids | |
WO2020156189A1 (zh) | 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途 | |
WO2021041970A1 (en) | Perk inhibiting imidazolopyrazine compounds | |
JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
CN110545814A (zh) | 趋化因子cxcr4受体调节剂及其相关用途 | |
AU2021393988A1 (en) | Substituted pyrazolo piperidine carboxylic acids | |
CA3203698A1 (en) | 2-pyridone derivative, and preparation method therefor and pharmaceutical application thereof | |
CA3152508A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
CN105524053B (zh) | 四氢苯并噻吩化合物 | |
PH12016501215B1 (en) | Azaindole derivative | |
KR20220068224A (ko) | Perk 억제 화합물 | |
CN114149423B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
WO2024067566A1 (zh) | 饱和环类衍生物、包含其的药物组合物及其医药用途 | |
WO2023116763A1 (zh) | 一种哒嗪类化合物、其药物组合物及应用 | |
CN117800895A (zh) | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |